Colorado 2024 Regular Session

Colorado Senate Bill SB124 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
	1	+	Second Regular Session
	2	+	Seventy-fourth General Assembly
	3	+	STATE OF COLORADO
	4	+	REREVISED
	5	+	This Version Includes All Amendments
	6	+	Adopted in the Second House
	7	+	LLS NO. 24-0481.01 Brita Darling x2241
1	8		SENATE BILL 24-124
2		-	BY SENATOR(S) Michaelson Jenet and Rich, Buckner, Cutter, Exum,
3		-	Ginal, Gonzales, Hansen, Hinrichsen, Kirkmeyer, Kolker, Marchman,
4		-	Mullica, Pelton B., Pelton R., Priola, Roberts, Will, Winter F., Fenberg;
5		-	also REPRESENTATIVE(S) Hartsook and Duran, Bird, Boesenecker,
6		-	Brown, English, Hamrick, Jodeh, Kipp, Lieder, Lindsay, Lukens,
7		-	McCormick, McLachlan, Rutinel, Titone, McCluskie.
	9	+	Senate Committees House Committees
	10	+	Health & Human Services Health & Human Services
	11	+	Appropriations
	12	+	A BILL FOR AN ACT
8	13		C
9		-	ONCERNING REQUIRING HEALTH -CARE COVERAGE FOR BIOMARKER
10		-	TESTING
11		-	.
12		-
13		-	Be it enacted by the General Assembly of the State of Colorado:
14		-	SECTION 1. In Colorado Revised Statutes, 10-16-104, add (28) as
15		-	follows:
16		-	10-16-104. Mandatory coverage provisions - definitions - rules.
17		-	(28) Biomarker testing. (a) A
18		-	LL LARGE GROUP HEALTH BENEFIT PLANS
19		-	AND
20		-	, TO THE EXTENT THAT SUCH COVERAGE IS NOT IN ADDITION TO THE
21		-	BENEFITS PROVIDED PURSUANT TO THE BENCHMARK PLAN
22		-	, ALL INDIVIDUAL
23		-	AND SMALL GROUP HEALTH BENEFIT PLANS SHALL PROVIDE COVERAGE FOR
24		-	BIOMARKER TESTING PURSUANT TO THIS SUBSECTION
25		-	(28).
26		-	NOTE: This bill has been prepared for the signatures of the appropriate legislative
27		-	officers and the Governor. To determine whether the Governor has signed the bill
28		-	or taken other action on it, please consult the legislative status sheet, the legislative
29		-	history, or the Session Laws.
30		-	________
31		-	Capital letters or bold & italic numbers indicate new material added to existing law; dashes
32		-	through words or numbers indicate deletions from existing law and such material is not part of
33		-	the act. (b) COVERAGE MUST INCLUDE BIOMARKER TESTING FOR DIAGNOSIS ,
34		-	TREATMENT, APPROPRIATE MANAGEMENT , AND ONGOING MONITORING OF A
35		-	COVERED PERSON
36		-	'S DISEASE OR CONDITION TO GUIDE TREATMENT DECISIONS
37		-	WHEN THE TEST IS SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE
38		-	,
39		-	INCLUDING:
	14	+	ONCERNING REQUIRING HEALTH -CARE COVERAGE FOR BIOMARKER101
	15	+	TESTING.102
	16	+	Bill Summary
	17	+	(Note: This summary applies to this bill as introduced and does
	18	+	not reflect any amendments that may be subsequently adopted. If this bill
	19	+	passes third reading in the house of introduction, a bill summary that
	20	+	applies to the reengrossed version of this bill will be available at
	21	+	http://leg.colorado.gov
	22	+	.)
	23	+	The bill requires all individual and group health benefit plans to
	24	+	provide coverage for biomarker testing to guide treatment decisions if the
	25	+	testing is supported by medical and scientific evidence. The bill defines
	26	+	"biomarker testing" as an analysis of a patient's tissue, blood, or other
	27	+	biospecimen for the presence of an indicator of normal biological
	28	+	processes, pathogenic processes, or pharmacologic responses to a specific
	29	+	HOUSE
	30	+	3rd Reading Unamended
	31	+	May 5, 2024
	32	+	HOUSE
	33	+	Amended 2nd Reading
	34	+	May 4, 2024
	35	+	SENATE
	36	+	3rd Reading Unamended
	37	+	April 26, 2024
	38	+	SENATE
	39	+	Amended 2nd Reading
	40	+	April 25, 2024
	41	+	SENATE SPONSORSHIP
	42	+	Michaelson Jenet and Rich, Buckner, Cutter, Exum, Fenberg, Ginal, Gonzales, Hansen,
	43	+	Hinrichsen, Kirkmeyer, Kolker, Marchman, Mullica, Pelton B., Pelton R., Priola, Roberts,
	44	+	Will, Winter F.
	45	+	HOUSE SPONSORSHIP
	46	+	Hartsook and Duran, Bird, Boesenecker, Brown, English, Hamrick, Jodeh, Kipp, Lieder,
	47	+	Lindsay, Lukens, McCluskie, McCormick, McLachlan, Rutinel, Titone
	48	+	Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.
	49	+	Capital letters or bold & italic numbers indicate new material to be added to existing law.
	50	+	Dashes through the words or numbers indicate deletions from existing law. therapeutic intervention. The required testing under the bill does not
	51	+	include biomarker testing for screening purposes or direct-to-consumer
	52	+	genetic tests.
	53	+	The bill requires the commissioner of insurance to implement
	54	+	biomarker testing coverage for all individual and group health benefit
	55	+	plans issued or renewed on or after January 1, 2026.
	56	+	Biomarker testing is subject to the health benefit plan's annual
	57	+	deductibles, copayment, or coinsurance but is not subject to any annual
	58	+	or lifetime maximum benefit limit.
	59	+	Subject to federal authorization and federal financial participation,
	60	+	beginning July 1, 2025, the bill includes coverage for biomarker testing
	61	+	as part of the state medical assistance program to guide treatment
	62	+	decisions if the testing is supported by medical and scientific evidence.
	63	+	The bill requires the medical assistance program to have a clear,
	64	+	easily accessible appeals process if biomarker testing is denied.
	65	+	Be it enacted by the General Assembly of the State of Colorado:1
	66	+	SECTION 1. In Colorado Revised Statutes, 10-16-104, add (27)2
	67	+	as follows:3
	68	+	10-16-104. Mandatory coverage provisions - definitions -4
	69	+	rules. (27) Biomarker testing. (a) A
	70	+	LL LARGE GROUP HEALTH BENEFIT
	71	+	5
	72	+	PLANS AND, TO THE EXTENT THAT SUCH COVERAGE IS NOT IN ADDITION TO6
	73	+	THE BENEFITS PROVIDED PURSUANT TO THE BENCHMARK PLAN , ALL7
	74	+	INDIVIDUAL AND SMALL GROUP HEALTH BENEFIT PLANS SHALL PROVIDE8
	75	+	COVERAGE FOR BIOMARKER TESTING PURSUANT TO THIS SUBSECTION (27).9
	76	+	(b) C
	77	+	OVERAGE MUST INCLUDE BIOMARKER TESTING FOR10
	78	+	DIAGNOSIS, TREATMENT, APPROPRIATE MANAGEMENT , AND ONGOING11
	79	+	MONITORING OF A COVERED PERSON 'S DISEASE OR CONDITION TO GUIDE12
	80	+	TREATMENT DECISIONS WHEN THE TEST IS SUPPORTED BY MEDICAL AND13
	81	+	SCIENTIFIC EVIDENCE, INCLUDING:14
40	82		(I) L
41		-	ABELED INDICATIONS FOR AN FDA-APPROVED OR
42		-	FDA-CLEARED TEST;
	83	+	ABELED INDICATIONS FOR AN FDA-APPROVED OR15
	84	+	FDA-
	85	+	CLEARED TEST;16
43	86		(II) I
44		-	NDICATED TESTS FOR AN FDA-APPROVED DRUG;
45		-	(III) W
46		-	ARNINGS AND PRECAUTIONS ON FDA-APPROVED DRUG
47		-	LABELS
48		-	;
	87	+	NDICATED TESTS FOR AN FDA-APPROVED DRUG;17
	88	+	124-2- (III) WARNINGS AND PRECAUTIONS ON FDA-APPROVED DRUG1
	89	+	LABELS;2
49	90		(IV) C
50		-	ENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL
51		-	COVERAGE DETERMINATIONS OR MEDICARE ADMINISTRATIVE CONTRACTOR
52		-	LOCAL COVERAGE DETERMINATIONS
53		-	; OR
54		-	(V) NATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES ,
55		-	CONSENSUS STATEMENTS , AND PEER-REVIEWED STUDIES.
	91	+	ENTERS FOR MEDICARE AND MEDICAID SERVICES NATIONAL3
	92	+	COVERAGE DETERMINATIONS OR MEDICARE ADMINISTRATIVE4
	93	+	CONTRACTOR LOCAL COVERAGE DETERMINATIONS ; OR5
	94	+	(V) N
	95	+	ATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES ,
	96	+	6
	97	+	CONSENSUS STATEMENTS , AND PEER-REVIEWED STUDIES.7
56	98		(c) T
57		-	HE COVERAGE REQUIRED BY THIS SUBSECTION (28) IS SUBJECT
58		-	TO ANNUAL DEDUCTIBLES
59		-	, COPAYMENTS, OR COINSURANCE REQUIREMENTS
60		-	UNDER THE HEALTH BENEFIT PLAN BUT IS NOT SUBJECT TO ANY ANNUAL OR
61		-	LIFETIME MAXIMUM BENEFIT LIMIT
62		-	.
	99	+	HE COVERAGE REQUIRED BY THIS SUBSECTION (27) IS SUBJECT8
	100	+	TO ANNUAL DEDUCTIBLES , COPAYMENTS , OR COINSURANCE9
	101	+	REQUIREMENTS UNDER THE HEALTH BENEFIT PLAN BUT IS NOT SUBJECT TO10
	102	+	ANY ANNUAL OR LIFETIME MAXIMUM BENEFIT LIMIT .11
63	103		(d) T
64		-	HE COVERAGE REQUIRED BY THIS SUBSECTION (28) MUST BE
65		-	PROVIDED IN A MANNER THAT LIMITS UNREASONABLE DISRUPTIONS IN CARE
66		-	,
67		-	INCLUDING LIMITING THE NEED FOR MULTIPLE BIOPSIES OR BIOSPECIMEN
68		-	SAMPLES
69		-	.
	104	+	HE COVERAGE REQUIRED BY THIS SUBSECTION (27) MUST BE12
	105	+	PROVIDED IN A MANNER THAT LIMITS UNREASONABLE DISRUPTIONS IN13
	106	+	CARE, INCLUDING LIMITING THE NEED FOR MULTIPLE BIOPSIES OR14
	107	+	BIOSPECIMEN SAMPLES.15
70	108		(e) N
71		-	OTHING IN THIS SUBSECTION (28) SHALL BE CONSTRUED TO
72		-	REQUIRE COVERAGE FOR BIOMARKER TESTING FOR SCREENING PURPOSES
73		-	.
	109	+	OTHING IN THIS SUBSECTION (27) SHALL BE CONSTRUED TO16
	110	+	REQUIRE COVERAGE FOR BIOMARKER TESTING FOR SCREENING PURPOSES .17
74	111		(f) A
75		-	CARRIER MAY REQUIRE PRIOR AUTHORIZATION ~~FOR BIOMARKER~~
76		-	TESTING IN THE SAME MANNER THAT PRIOR ~~AUTHORIZATION IS REQUIRED~~
77		-	FOR ANY OTHER COVERED BENEFIT AND CONSISTENT ~~WITH SECTION~~
78		-	10-16-112.5.
	112	+	CARRIER MAY REQUIRE PRIOR AUTHORIZATION FOR18
	113	+	BIOMARKER TESTING IN THE SAME MANNER THAT PRIOR AUTHORIZATION19
	114	+	IS REQUIRED FOR ANY OTHER COVERED BENEFIT AND CONSISTENT WITH20
	115	+	SECTION 10-16-112.5.21
79	116		(g) (I) W
80	117		ITHIN ONE HUNDRED TWENTY DAYS AFTER THE EFFECTIVE
81		-	~~PAGE 2-SENATE BILL 24-124 DATE OF THIS SUBSECTION (28), THE DIVISION SHALL SUBMIT TO THE~~
82		-	~~FEDERAL DEPARTMENT~~ OF ~~HEALTH AND HUMAN SERVICES~~
83		-	:
	118	+	22
	119	+	DATE OF THIS SECTION, THE DIVISION SHALL SUBMIT TO THE FEDERAL23
	120	+	DEPARTMENT OF HEALTH AND HUMAN SERVICES :24
84	121		(A) A
85	122		DETERMINATION AS TO WHETHER THE BENEFIT SPECIFIED IN
86		-	THIS SUBSECTION
87		-	(28) IS IN ADDITION TO ESSENTIAL HEALTH BENEFITS AND
88		-	WOULD BE SUBJECT TO DEFRAYAL BY THE STATE PURSUANT TO
89		-	42 U.S.C.
90		-	SEC. 18031 (d)(3)(B); AND
91		-	(B) A REQUEST THAT THE FEDERAL DEPARTMENT OF HEALTH AND
92		-	HUMAN SERVICES CONFIRM THE DIVISION
93		-	'S DETERMINATION WITHIN SIXTY
94		-	DAYS AFTER RECEIPT OF THE DIVISION
95		-	'S REQUEST AND SUBMISSION OF ITS
96		-	DETERMINATION
97		-	.
	123	+	25
	124	+	THIS SUBSECTION (27) IS IN ADDITION TO ESSENTIAL HEALTH BENEFITS AND26
	125	+	WOULD BE SUBJECT TO DEFRAYAL BY THE STATE PURSUANT TO 42 U.S.C.27
	126	+	124
	127	+	-3- SEC. 18031 (d)(3)(B); AND1
	128	+	(B) A
	129	+	REQUEST THAT THE FEDERAL DEPARTMENT OF HEALTH AND
	130	+	2
	131	+	HUMAN SERVICES CONFIRM THE DIVISION'S DETERMINATION WITHIN SIXTY3
	132	+	DAYS AFTER RECEIPT OF THE DIVISION'S REQUEST AND SUBMISSION OF ITS4
	133	+	DETERMINATION.5
98	134		(II) T
99		-	HIS SUBSECTION (28) APPLIES TO, AND THE DIVISION SHALL
100		-	IMPLEMENT THE PROVISIONS OF THIS SUBSECTION
101		-	(28) FOR, LARGE
102		-	EMPLOYER HEALTH BENEFIT PLANS ISSUED OR RENEWED IN THIS STATE ON
103		-	OR AFTER
104		-	JANUARY 1, 2025.
	135	+	HIS SUBSECTION (27) APPLIES TO, AND THE DIVISION SHALL
	136	+	6
	137	+	IMPLEMENT THE PROVISIONS OF THIS SUBSECTION (27) FOR, LARGE7
	138	+	EMPLOYER HEALTH BENEFIT PLANS ISSUED OR RENEWED IN THIS STATE ON8
	139	+	OR AFTER JANUARY 1, 2025.9
105	140		(III) T
106		-	HIS SUBSECTION (28) APPLIES TO, AND THE DIVISION SHALL
107		-	~~IMPLEMENT THE REQUIREMENTS OF THIS SUBSECTION~~
108		-	(28) FOR, ~~INDIVIDUAL~~
109		-	AND SMALL GROUP HEALTH BENEFIT PLANS ISSUED ~~OR RENEWED IN THIS~~
110		-	STATE TWELVE MONTHS AFTER THE EARLIER OF ~~THE FOLLOWING~~
111		-	:
	141	+	HIS SUBSECTION (27) APPLIES TO, AND THE DIVISION SHALL
	142	+	10
	143	+	IMPLEMENT THE REQUIREMENTS OF THIS SUBSECTION (27) FOR,11
	144	+	INDIVIDUAL AND SMALL GROUP HEALTH BENEFIT PLANS ISSUED OR12
	145	+	RENEWED IN THIS STATE TWELVE MONTHS AFTER THE EARLIER OF THE13
	146	+	FOLLOWING:14
112	147		(A) T
113	148		HE DIVISION RECEIVES CONFIRMATION FROM THE FEDERAL
114		-	DEPARTMENT OF HEALTH AND HUMAN SERVICES THAT THE COVERAGE
115		-	SPECIFIED IN THIS SUBSECTION
116		-	(28) DOES NOT CONSTITUTE AN ADDITIONAL
117		-	BENEFIT THAT REQUIRES DEFRAYAL BY THE STATE PURSUANT TO
118		-	42 U.S.C.
119		-	SEC. 18031 (d)(3)(B);
	149	+	15
	150	+	DEPARTMENT OF HEALTH AND HUMAN SERVICES THAT THE COVERAGE16
	151	+	SPECIFIED IN THIS SUBSECTION (27) DOES NOT CONSTITUTE AN ADDITIONAL17
	152	+	BENEFIT THAT REQUIRES DEFRAYAL BY THE STATE PURSUANT TO 42 U.S.C.18
	153	+	SEC. 18031 (d)(3)(B);19
120	154		(B) T
121	155		HE FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES
122		-	HAS OTHERWISE INFORMED THE DIVISION THAT THE COVERAGE DOES NOT
123		-	REQUIRE STATE DEFRAYAL PURSUANT TO
124		-	42 U.S.C. SEC. 18031 (d)(3)(B); OR
125		-	(C) MORE THAN THREE HUNDRED SIXTY -FIVE DAYS HAVE PASSED
126		-	SINCE THE DIVISION SUBMITTED ITS DETERMINATION AND REQUEST FOR
127		-	CONFIRMATION THAT THE COVERAGE SPECIFIED IN THIS SUBSECTION
128		-	(28) IS
129		-	NOT AN ADDITIONAL BENEFIT THAT REQUIRES STATE DEFRAYAL PURSUANT
130		-	TO
131		-	42 U.S.C. SEC. 18031 (d)(3)(B), AND THE FEDERAL DEPARTMENT OF
132		-	HEALTH AND HUMAN SERVICES HAS FAILED TO RESPOND TO THE REQUEST
133		-	WITHIN THAT PERIOD
134		-	, IN WHICH CASE THE DIVISION SHALL CONSIDER THE
135		-	PAGE 3-SENATE BILL 24-124 FEDERAL DEPARTMENT OF HEALTH AND HUMAN SERVICES ' UNREASONABLE
136		-	DELAY A PRECLUSION FROM REQUIRING DEFRAYAL BY THE STATE
137		-	.
138		-	(h) T
139		-	HE COMMISSIONER SHALL IMPLEMENT THIS SUBSECTION (28)
140		-	AND SHALL ADOPT RULES CONSISTENT WITH AND AS ARE NECESSARY TO
141		-	IMPLEMENT THIS SUBSECTION
142		-	(28).
143		-	(i) A
144		-	S USED IN THIS SUBSECTION (28):
	156	+	20
	157	+	HAS OTHERWISE INFORMED THE DIVISION THAT THE COVERAGE DOES NOT21
	158	+	REQUIRE STATE DEFRAYAL PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B);22
	159	+	OR23
	160	+	(C) M
	161	+	ORE THAN THREE HUNDRED SIXTY -FIVE DAYS HAVE PASSED
	162	+	24
	163	+	SINCE THE DIVISION SUBMITTED ITS DETERMINATION AND REQUEST FOR25
	164	+	CONFIRMATION THAT THE COVERAGE SPECIFIED IN THIS SUBSECTION (27)26
	165	+	IS NOT AN ADDITIONAL BENEFIT THAT REQUIRES STATE DEFRAYAL27
	166	+	124
	167	+	-4- PURSUANT TO 42 U.S.C. SEC. 18031 (d)(3)(B), AND THE FEDERAL1
	168	+	DEPARTMENT OF HEALTH AND HUMAN SERVICES HAS FAILED TO RESPOND2
	169	+	TO THE REQUEST WITHIN THAT PERIOD , IN WHICH CASE THE DIVISION3
	170	+	SHALL CONSIDER THE FEDERAL DEPARTMENT OF HEALTH AND HUMAN4
	171	+	SERVICES' UNREASONABLE DELAY A PRECLUSION FROM REQUIRING5
	172	+	DEFRAYAL BY THE STATE.6
	173	+	(h) THE COMMISSIONER SHALL IMPLEMENT THIS SUBSECTION (27)7
	174	+	AND SHALL ADOPT RULES CONSISTENT WITH AND AS ARE NECESSARY TO8
	175	+	IMPLEMENT THIS SUBSECTION (27).9
	176	+	(i) AS USED IN THIS SUBSECTION (27):10
145	177		(I) "B
146		-	IOMARKER" MEANS A CHARACTERISTIC THAT IS OBJECTIVELY
147		-	MEASURED AND EVALUATED AS AN INDICATOR OF NORMAL BIOLOGICAL
148		-	PROCESSES
149		-	, PATHOGENIC PROCESSES, OR PHARMACOLOGIC RESPONSES TO A
150		-	SPECIFIC THERAPEUTIC INTERVENTION
151		-	, INCLUDING KNOWN GENE -DRUG
152		-	INTERACTIONS FOR MEDICATIONS BEING CONSIDERED FOR USE OR ALREADY
153		-	BEING ADMINISTERED
154		-	. "BIOMARKER" INCLUDES GENE MUTATIONS ,
155		-	CHARACTERISTICS OF GENES, OR PROTEIN EXPRESSION.
	178	+	IOMARKER" MEANS A CHARACTERISTIC THAT IS OBJECTIVELY11
	179	+	MEASURED AND EVALUATED AS AN INDICATOR OF NORMAL BIOLOGICAL12
	180	+	PROCESSES, PATHOGENIC PROCESSES, OR PHARMACOLOGIC RESPONSES TO13
	181	+	A SPECIFIC THERAPEUTIC INTERVENTION, INCLUDING KNOWN GENE-DRUG14
	182	+	INTERACTIONS FOR MEDICATIONS BEING CONSIDERED FOR USE OR15
	183	+	ALREADY BEING ADMINISTERED . "BIOMARKER" INCLUDES GENE16
	184	+	MUTATIONS, CHARACTERISTICS OF GENES, OR PROTEIN EXPRESSION.17
156	185		(II) "B
157		-	IOMARKER TESTING" MEANS THE ANALYSIS OF A PATIENT 'S
158		-	TISSUE
159		-	, BLOOD, OR OTHER BIOSPECIMEN FOR THE PRESENCE OF A
160		-	BIOMARKER
161		-	. "BIOMARKER TESTING" INCLUDES SINGLE-ANALYTE TESTS,
162		-	MULTIPLEX PANEL TESTS, PROTEIN EXPRESSION, AND WHOLE EXOME, WHOLE
163		-	GENOME
164		-	, AND WHOLE TRANSCRIPTOME SEQUENCING . "BIOMARKER TESTING"
165		-	DOES NOT INCLUDE DIRECT-TO-CONSUMER GENETIC TESTS.
	186	+	IOMARKER TESTING" MEANS THE ANALYSIS OF A PATIENT'S18
	187	+	TISSUE, BLOOD, OR OTHER BIOSPECIMEN FOR THE PRESENCE OF A19
	188	+	BIOMARKER. "BIOMARKER TESTING" INCLUDES SINGLE-ANALYTE TESTS,20
	189	+	MULTIPLEX PANEL TESTS, PROTEIN EXPRESSION, AND WHOLE EXOME ,21
	190	+	WHOLE GENOME, AND WHOLE TRANSCRIPTOME SEQUENCING . "BIOMARKER22
	191	+	TESTING" DOES NOT INCLUDE DIRECT-TO-CONSUMER GENETIC TESTS.23
166	192		(III) "C
167		-	ONSENSUS STATEMENTS" MEANS STATEMENTS DEVELOPED BY
168		-	AN INDEPENDENT
169		-	, MULTIDISCIPLINARY PANEL OF EXPERTS UTILIZING A
170		-	TRANSPARENT METHODOLOGY AND REPORTING STRUCTURE AND WITH A
171		-	CONFLICT OF INTEREST POLICY
172		-	. CONSENSUS STATEMENTS ARE DEVELOPED
173		-	FOR SPECIFIC CLINICAL CIRCUMSTANCES AND ARE BASED ON THE BEST
174		-	AVAILABLE EVIDENCE FOR THE PURPOSE OF OPTIMIZING THE OUTCOMES OF
175		-	CLINICAL CARE
176		-	.
	193	+	ONSENSUS STATEMENTS" MEANS STATEMENTS DEVELOPED24
	194	+	BY AN INDEPENDENT, MULTIDISCIPLINARY PANEL OF EXPERTS UTILIZING25
	195	+	A TRANSPARENT METHODOLOGY AND REPORTING STRUCTURE AND WITH26
	196	+	A CONFLICT OF INTEREST POLICY . CONSENSUS STATEMENTS ARE27
	197	+	124
	198	+	-5- DEVELOPED FOR SPECIFIC CLINICAL CIRCUMSTANCES AND ARE BASED ON1
	199	+	THE BEST AVAILABLE EVIDENCE FOR THE PURPOSE OF OPTIMIZING THE2
	200	+	OUTCOMES OF CLINICAL CARE.3
177	201		(IV) "N
178		-	ATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES "
179		-	MEANS EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES DEVELOPED BY
180		-	INDEPENDENT ORGANIZATIONS OR MEDICAL PROFESSIONAL ~~SOCIETIES~~
181		-	UTILIZING A TRANSPARENT ~~METHODOL OGY~~ AND REPORTING ~~STRUCTURE AND~~
182		-	WITH A CONFLICT OF INTEREST POLICY
183		-	~~. CLINICAL PRACTICE~~ GUIDELINES:
	202	+	ATIONALLY RECOGNIZED CLINICAL PRACTICE GUIDELINES "4
	203	+	MEANS EVIDENCE-BASED CLINICAL PRACTICE GUIDELINES DEVELOPED BY5
	204	+	INDEPENDENT ORGANIZATIONS OR MEDICAL PROFESSIONAL SOCIETIES6
	205	+	UTILIZING A TRANSPARENT METHODOLOGY AND REPORTING STRUCTURE7
	206	+	AND WITH A CONFLICT OF INTEREST POLICY . CLINICAL PRACTICE8
	207	+	GUIDELINES:9
184	208		(A) E
185		-	STABLISH STANDARDS OF CARE INFORMED BY A SYSTEMATIC
186		-	REVIEW OF EVIDENCE AND AN ASSESSMENT OF THE BENEFITS AND RISKS OF
187		-	PAGE 4-SENATE BILL 24-124 ALTERNATIVE CARE OPTIONS; AND
188		-	(B) INCLUDE RECOMMENDATIONS INTENDED TO OPTIMIZE PATIENT
189		-	CARE
190		-	.
191		-	SECTION 2. Safety clause. The general assembly finds,
192		-	determines, and declares that this act is necessary for the immediate
193		-	preservation of the public peace, health, or safety or for appropriations for
194		-	PAGE 5-SENATE BILL 24-124 the support and maintenance of the departments of the state and state
195		-	institutions.
196		-	____________________________ ____________________________
197		-	Steve Fenberg
198		-	Julie McCluskie
199		-	PRESIDENT OF SPEAKER OF THE HOUSE
200		-	THE SENATE OF REPRESENTATIVES
201		-	____________________________ ____________________________
202		-	Cindi L. Markwell Robin Jones
203		-	SECRETARY OF CHIEF CLERK OF THE HOUSE
204		-	THE SENATE OF REPRESENTATIVES
205		-	APPROVED________________________________________
206		-	(Date and Time)
207		-	_________________________________________
208		-	Jared S. Polis
209		-	GOVERNOR OF THE STATE OF COLORADO
210		-	PAGE 6-SENATE BILL 24-124
	209	+	STABLISH STANDARDS OF CARE INFORMED BY A SYSTEMATIC10
	210	+	REVIEW OF EVIDENCE AND AN ASSESSMENT OF THE BENEFITS AND RISKS OF11
	211	+	ALTERNATIVE CARE OPTIONS; AND12
	212	+	(B) I
	213	+	NCLUDE RECOMMENDATIONS INTENDED TO OPTIMIZE PATIENT13
	214	+	CARE.14
	215	+	15
	216	+	SECTION 2. Safety clause. The general assembly finds,16
	217	+	determines, and declares that this act is necessary for the immediate17
	218	+	preservation of the public peace, health, or safety or for appropriations for18
	219	+	the support and maintenance of the departments of the state and state19
	220	+	institutions.20
	221	+	124
	222	+	-6-